| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 30 | 2026 | 97 | 10.260 |
Why?
|
| Pleural Neoplasms | 26 | 2026 | 84 | 10.010 |
Why?
|
| Lung Neoplasms | 48 | 2026 | 1545 | 8.690 |
Why?
|
| Thoracic Outlet Syndrome | 9 | 2023 | 20 | 5.410 |
Why?
|
| Thoracic Surgical Procedures | 12 | 2026 | 105 | 5.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 16 | 2026 | 357 | 4.750 |
Why?
|
| Thymus Neoplasms | 10 | 2019 | 39 | 4.230 |
Why?
|
| Robotic Surgical Procedures | 8 | 2026 | 226 | 3.540 |
Why?
|
| Pneumonectomy | 13 | 2026 | 154 | 3.060 |
Why?
|
| Thymoma | 6 | 2019 | 19 | 2.960 |
Why?
|
| Thoracic Wall | 3 | 2026 | 40 | 2.240 |
Why?
|
| Thymectomy | 5 | 2019 | 24 | 2.130 |
Why?
|
| Ribs | 7 | 2023 | 51 | 2.100 |
Why?
|
| Thoracoscopy | 3 | 2026 | 41 | 2.060 |
Why?
|
| Robotics | 4 | 2023 | 102 | 1.970 |
Why?
|
| Adenocarcinoma | 10 | 2022 | 972 | 1.810 |
Why?
|
| Thoracic Neoplasms | 3 | 2026 | 36 | 1.630 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2019 | 41 | 1.630 |
Why?
|
| Neoplasm Staging | 16 | 2026 | 1287 | 1.600 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2026 | 51 | 1.510 |
Why?
|
| Thoracic Surgery | 4 | 2026 | 163 | 1.430 |
Why?
|
| Biomarkers, Tumor | 10 | 2025 | 1586 | 1.420 |
Why?
|
| Humans | 127 | 2026 | 131163 | 1.310 |
Why?
|
| Pleura | 5 | 2018 | 27 | 1.270 |
Why?
|
| Esophagectomy | 3 | 2021 | 71 | 1.240 |
Why?
|
| Decompression, Surgical | 5 | 2021 | 83 | 1.130 |
Why?
|
| Killer Cells, Natural | 6 | 2026 | 355 | 1.100 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 36 | 1.090 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2024 | 2065 | 1.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 2026 | 1.070 |
Why?
|
| Surgeons | 4 | 2024 | 289 | 1.050 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2019 | 1272 | 1.040 |
Why?
|
| Neoadjuvant Therapy | 7 | 2026 | 400 | 1.020 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2026 | 821 | 1.020 |
Why?
|
| Laparoscopy | 2 | 2024 | 541 | 1.000 |
Why?
|
| B7-H1 Antigen | 5 | 2024 | 136 | 0.990 |
Why?
|
| Esophageal Neoplasms | 6 | 2022 | 388 | 0.940 |
Why?
|
| Tumor Microenvironment | 12 | 2026 | 713 | 0.790 |
Why?
|
| Treatment Outcome | 21 | 2026 | 12936 | 0.740 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2018 | 387 | 0.740 |
Why?
|
| Lung | 4 | 2022 | 1535 | 0.730 |
Why?
|
| Aged | 29 | 2026 | 21025 | 0.710 |
Why?
|
| GPI-Linked Proteins | 2 | 2024 | 110 | 0.710 |
Why?
|
| Cervical Rib | 1 | 2021 | 1 | 0.700 |
Why?
|
| Prognosis | 13 | 2022 | 4886 | 0.700 |
Why?
|
| Middle Aged | 31 | 2026 | 28601 | 0.680 |
Why?
|
| Genetic Therapy | 3 | 2025 | 713 | 0.670 |
Why?
|
| Female | 48 | 2026 | 70963 | 0.650 |
Why?
|
| Antigens, Neoplasm | 3 | 2018 | 393 | 0.650 |
Why?
|
| Dendritic Cells | 8 | 2024 | 439 | 0.640 |
Why?
|
| Racism | 1 | 2021 | 56 | 0.640 |
Why?
|
| Morphine | 1 | 2020 | 81 | 0.630 |
Why?
|
| Cisplatin | 2 | 2021 | 274 | 0.630 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 1826 | 0.630 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 279 | 0.620 |
Why?
|
| Sarcopenia | 1 | 2020 | 56 | 0.620 |
Why?
|
| Male | 47 | 2026 | 64957 | 0.610 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2026 | 144 | 0.610 |
Why?
|
| Povidone-Iodine | 1 | 2019 | 7 | 0.590 |
Why?
|
| Surgical Flaps | 1 | 2021 | 183 | 0.570 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 15 | 0.570 |
Why?
|
| Margins of Excision | 1 | 2019 | 60 | 0.570 |
Why?
|
| Retrospective Studies | 23 | 2024 | 17753 | 0.570 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 6797 | 0.560 |
Why?
|
| Stomach | 1 | 2021 | 274 | 0.560 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2009 | 272 | 0.550 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 164 | 0.540 |
Why?
|
| Frailty | 1 | 2020 | 140 | 0.540 |
Why?
|
| Liposarcoma | 1 | 2018 | 24 | 0.540 |
Why?
|
| Hyperthermia, Induced | 1 | 2018 | 50 | 0.530 |
Why?
|
| Survival Rate | 8 | 2022 | 2114 | 0.530 |
Why?
|
| Deoxycytidine | 1 | 2018 | 80 | 0.530 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2018 | 750 | 0.530 |
Why?
|
| Immunotherapy | 7 | 2026 | 768 | 0.510 |
Why?
|
| Parapsychology | 1 | 2017 | 1 | 0.510 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 195 | 0.500 |
Why?
|
| Certification | 1 | 2017 | 71 | 0.500 |
Why?
|
| Radiosurgery | 2 | 2015 | 148 | 0.490 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 46 | 0.490 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 9 | 0.490 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 125 | 0.490 |
Why?
|
| Gene Expression Profiling | 3 | 2025 | 1801 | 0.490 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2016 | 29 | 0.480 |
Why?
|
| Macrophages, Alveolar | 1 | 2016 | 52 | 0.480 |
Why?
|
| Cell Line, Tumor | 11 | 2026 | 3748 | 0.480 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 13 | 0.460 |
Why?
|
| Respiratory Tract Fistula | 1 | 2015 | 15 | 0.460 |
Why?
|
| Pleural Diseases | 1 | 2015 | 31 | 0.450 |
Why?
|
| Esophageal Achalasia | 1 | 2016 | 50 | 0.450 |
Why?
|
| Learning Curve | 1 | 2015 | 54 | 0.440 |
Why?
|
| Castleman Disease | 1 | 2015 | 13 | 0.440 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 194 | 0.440 |
Why?
|
| Mediastinal Diseases | 1 | 2015 | 14 | 0.440 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 33 | 0.440 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 40 | 0.430 |
Why?
|
| Pulmonary Alveoli | 1 | 2015 | 139 | 0.430 |
Why?
|
| Transcriptome | 2 | 2019 | 1103 | 0.430 |
Why?
|
| Tumor Burden | 1 | 2015 | 240 | 0.430 |
Why?
|
| Radiography | 1 | 2016 | 743 | 0.420 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2014 | 8 | 0.420 |
Why?
|
| Postoperative Complications | 5 | 2017 | 3147 | 0.410 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 631 | 0.410 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2016 | 79 | 0.410 |
Why?
|
| Encephalitis | 1 | 2015 | 122 | 0.390 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 178 | 0.390 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 142 | 0.390 |
Why?
|
| Survival Analysis | 4 | 2017 | 1483 | 0.390 |
Why?
|
| Databases, Factual | 6 | 2018 | 1240 | 0.380 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 638 | 0.380 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 324 | 0.380 |
Why?
|
| Adult | 21 | 2021 | 31282 | 0.370 |
Why?
|
| Thoracotomy | 3 | 2019 | 107 | 0.370 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2017 | 156 | 0.370 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 1378 | 0.360 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2012 | 13 | 0.360 |
Why?
|
| Disease Management | 2 | 2015 | 558 | 0.350 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 554 | 0.350 |
Why?
|
| Coronary Artery Bypass | 1 | 2015 | 515 | 0.340 |
Why?
|
| Leiomyosarcoma | 1 | 2011 | 22 | 0.340 |
Why?
|
| Antigen Presentation | 3 | 2024 | 110 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 425 | 0.330 |
Why?
|
| Combined Modality Therapy | 7 | 2026 | 1216 | 0.330 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2026 | 155 | 0.330 |
Why?
|
| Decision Making | 1 | 2016 | 726 | 0.330 |
Why?
|
| Cerebellum | 1 | 2015 | 441 | 0.330 |
Why?
|
| Registries | 2 | 2024 | 1634 | 0.330 |
Why?
|
| Genomics | 3 | 2018 | 1621 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 75 | 0.320 |
Why?
|
| Myeloid Cells | 1 | 2011 | 113 | 0.320 |
Why?
|
| Time Factors | 8 | 2024 | 6196 | 0.320 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 100 | 0.320 |
Why?
|
| Hernia, Obturator | 1 | 2010 | 4 | 0.320 |
Why?
|
| Risk Assessment | 6 | 2021 | 3711 | 0.310 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5196 | 0.310 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 905 | 0.310 |
Why?
|
| Liver | 6 | 2009 | 1796 | 0.310 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 124 | 0.310 |
Why?
|
| Receptors, KIR | 1 | 2009 | 12 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 1071 | 0.290 |
Why?
|
| United States | 11 | 2024 | 12072 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 981 | 0.290 |
Why?
|
| Risk Factors | 8 | 2026 | 11074 | 0.290 |
Why?
|
| Hepatitis, Viral, Animal | 1 | 2008 | 3 | 0.280 |
Why?
|
| Animals | 24 | 2026 | 33912 | 0.280 |
Why?
|
| CD11c Antigen | 1 | 2008 | 40 | 0.280 |
Why?
|
| Societies, Medical | 3 | 2026 | 798 | 0.270 |
Why?
|
| Clinical Competence | 1 | 2015 | 1050 | 0.270 |
Why?
|
| Mice | 18 | 2026 | 18301 | 0.270 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 2304 | 0.270 |
Why?
|
| Odds Ratio | 3 | 2017 | 1211 | 0.260 |
Why?
|
| Patient Selection | 4 | 2020 | 729 | 0.260 |
Why?
|
| Reoperation | 3 | 2017 | 818 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1129 | 0.260 |
Why?
|
| Postoperative Period | 2 | 2019 | 331 | 0.260 |
Why?
|
| Macrophages | 4 | 2022 | 667 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 4 | 2026 | 1295 | 0.250 |
Why?
|
| Meckel Diverticulum | 1 | 2006 | 10 | 0.250 |
Why?
|
| Hemoperitoneum | 1 | 2006 | 9 | 0.250 |
Why?
|
| Diverticulitis | 1 | 2006 | 7 | 0.250 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 136 | 0.240 |
Why?
|
| Neurofibromin 2 | 1 | 2026 | 10 | 0.240 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 475 | 0.240 |
Why?
|
| Cohort Studies | 5 | 2022 | 5063 | 0.240 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 127 | 0.230 |
Why?
|
| Adenoviridae | 1 | 2008 | 579 | 0.230 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2005 | 123 | 0.210 |
Why?
|
| Laparoscopes | 1 | 2024 | 5 | 0.210 |
Why?
|
| Neoplasms | 5 | 2024 | 3016 | 0.210 |
Why?
|
| Equipment Contamination | 1 | 2024 | 38 | 0.210 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 563 | 0.210 |
Why?
|
| Neoplasm Transplantation | 3 | 2021 | 358 | 0.200 |
Why?
|
| Watchful Waiting | 1 | 2024 | 73 | 0.200 |
Why?
|
| Equipment Design | 2 | 2024 | 512 | 0.200 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2023 | 22 | 0.200 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2003 | 6 | 0.190 |
Why?
|
| Facial Nerve | 1 | 2003 | 25 | 0.190 |
Why?
|
| Proteostasis | 1 | 2023 | 37 | 0.190 |
Why?
|
| Parotid Neoplasms | 1 | 2003 | 21 | 0.190 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2023 | 136 | 0.190 |
Why?
|
| Endoribonucleases | 1 | 2023 | 87 | 0.190 |
Why?
|
| Soot | 1 | 2022 | 14 | 0.190 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 65 | 0.190 |
Why?
|
| Skull Base Neoplasms | 1 | 2003 | 39 | 0.190 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 407 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 176 | 0.180 |
Why?
|
| Medical Audit | 1 | 2002 | 98 | 0.180 |
Why?
|
| Telemedicine | 2 | 2026 | 526 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2026 | 960 | 0.170 |
Why?
|
| Hepatectomy | 1 | 2002 | 131 | 0.170 |
Why?
|
| Tomography, Emission-Computed | 1 | 2001 | 35 | 0.170 |
Why?
|
| Biomimetics | 1 | 2021 | 17 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 463 | 0.170 |
Why?
|
| Young Adult | 5 | 2019 | 10103 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 500 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 619 | 0.170 |
Why?
|
| Drainage | 1 | 2002 | 250 | 0.170 |
Why?
|
| Kartagener Syndrome | 1 | 2021 | 12 | 0.170 |
Why?
|
| Situs Inversus | 1 | 2021 | 26 | 0.160 |
Why?
|
| Heterografts | 1 | 2021 | 191 | 0.160 |
Why?
|
| Apoptosis | 4 | 2021 | 1827 | 0.160 |
Why?
|
| Anastomotic Leak | 1 | 2021 | 36 | 0.160 |
Why?
|
| Swine | 1 | 2024 | 1186 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 573 | 0.160 |
Why?
|
| Carcinoma | 1 | 2003 | 291 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2024 | 6459 | 0.160 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 191 | 0.160 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 176 | 0.160 |
Why?
|
| Dissection | 1 | 2020 | 55 | 0.160 |
Why?
|
| Respiratory System | 1 | 2020 | 94 | 0.160 |
Why?
|
| Pain Measurement | 1 | 2021 | 353 | 0.160 |
Why?
|
| Logistic Models | 2 | 2015 | 1797 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 597 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2020 | 107 | 0.150 |
Why?
|
| T-Lymphocytes | 4 | 2016 | 1722 | 0.150 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 426 | 0.150 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2020 | 41 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 61 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2021 | 511 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2021 | 421 | 0.150 |
Why?
|
| Colorectal Neoplasms | 2 | 2005 | 621 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 144 | 0.140 |
Why?
|
| Peptides | 2 | 2024 | 708 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2008 | 23 | 0.140 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 68 | 0.140 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 109 | 0.140 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.140 |
Why?
|
| Pain | 1 | 2021 | 450 | 0.140 |
Why?
|
| Mutation | 4 | 2024 | 6099 | 0.140 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 101 | 0.140 |
Why?
|
| Attention | 1 | 2020 | 194 | 0.140 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2018 | 14 | 0.140 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2018 | 7 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 327 | 0.140 |
Why?
|
| Monitoring, Physiologic | 2 | 2017 | 376 | 0.140 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2017 | 13 | 0.130 |
Why?
|
| Cytokines | 4 | 2022 | 1339 | 0.130 |
Why?
|
| Solubility | 1 | 2017 | 117 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2021 | 687 | 0.130 |
Why?
|
| Biomarkers | 3 | 2022 | 3385 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2018 | 125 | 0.130 |
Why?
|
| Publication Bias | 1 | 2017 | 17 | 0.130 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 434 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 371 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 314 | 0.130 |
Why?
|
| Adolescent | 5 | 2019 | 20987 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2021 | 506 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 305 | 0.130 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2016 | 8 | 0.130 |
Why?
|
| Smoking | 2 | 2026 | 932 | 0.120 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 52 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2019 | 294 | 0.120 |
Why?
|
| Clodronic Acid | 1 | 2016 | 5 | 0.120 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 13 | 0.120 |
Why?
|
| Cetuximab | 1 | 2016 | 14 | 0.120 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 15 | 0.120 |
Why?
|
| Proteogenomics | 1 | 2018 | 111 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2016 | 90 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 357 | 0.120 |
Why?
|
| Uteroglobin | 1 | 2016 | 43 | 0.120 |
Why?
|
| Macrophage Activation | 1 | 2016 | 67 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2017 | 221 | 0.120 |
Why?
|
| Fetal Distress | 1 | 2016 | 13 | 0.120 |
Why?
|
| Maternal-Fetal Relations | 1 | 2016 | 19 | 0.120 |
Why?
|
| Lung Transplantation | 1 | 2021 | 363 | 0.120 |
Why?
|
| Standard of Care | 1 | 2017 | 133 | 0.120 |
Why?
|
| Models, Biological | 2 | 2018 | 1371 | 0.120 |
Why?
|
| Absorbable Implants | 1 | 2015 | 24 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 613 | 0.110 |
Why?
|
| Air | 1 | 2015 | 21 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2021 | 2465 | 0.110 |
Why?
|
| Bradycardia | 1 | 2016 | 58 | 0.110 |
Why?
|
| Heart Rate, Fetal | 1 | 2016 | 62 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2017 | 357 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Lymphocyte Activation | 3 | 2016 | 633 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.110 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 55 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 108 | 0.110 |
Why?
|
| Pneumothorax | 1 | 2016 | 82 | 0.110 |
Why?
|
| Efficiency | 1 | 2015 | 74 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2021 | 963 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2016 | 286 | 0.110 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 350 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 546 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1336 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 5 | 2021 | 975 | 0.100 |
Why?
|
| Cell Movement | 1 | 2018 | 876 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 152 | 0.100 |
Why?
|
| Interleukin-15 | 2 | 2021 | 104 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 480 | 0.100 |
Why?
|
| Hospitals, Low-Volume | 1 | 2014 | 36 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 570 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 688 | 0.100 |
Why?
|
| Receptors, IgG | 2 | 2015 | 59 | 0.100 |
Why?
|
| Hospitals, High-Volume | 1 | 2014 | 44 | 0.100 |
Why?
|
| Immunity, Innate | 2 | 2022 | 406 | 0.100 |
Why?
|
| Checklist | 1 | 2014 | 97 | 0.100 |
Why?
|
| Disease Progression | 2 | 2018 | 2200 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 688 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 992 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1410 | 0.100 |
Why?
|
| Length of Stay | 2 | 2013 | 1421 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2015 | 294 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 361 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 223 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 240 | 0.090 |
Why?
|
| Consensus | 3 | 2020 | 512 | 0.090 |
Why?
|
| Hernia, Diaphragmatic, Traumatic | 1 | 2012 | 6 | 0.090 |
Why?
|
| Herpesvirus 1, Human | 2 | 2004 | 41 | 0.090 |
Why?
|
| Propensity Score | 1 | 2014 | 271 | 0.090 |
Why?
|
| Inflammation | 2 | 2012 | 1489 | 0.090 |
Why?
|
| Transplantation, Heterologous | 3 | 2021 | 255 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 680 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 786 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1168 | 0.090 |
Why?
|
| Interleukin-4 | 1 | 2012 | 144 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1029 | 0.090 |
Why?
|
| Diaphragm | 1 | 2012 | 101 | 0.090 |
Why?
|
| Massachusetts | 1 | 2011 | 122 | 0.090 |
Why?
|
| Mice, Knockout | 6 | 2018 | 3819 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2602 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 633 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2021 | 1223 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2326 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 421 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 567 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2013 | 388 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 5 | 2024 | 4738 | 0.080 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 257 | 0.080 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2009 | 48 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2016 | 889 | 0.080 |
Why?
|
| Blood Cells | 1 | 2009 | 53 | 0.070 |
Why?
|
| Microsurgery | 1 | 2009 | 67 | 0.070 |
Why?
|
| Quality of Life | 1 | 2019 | 2082 | 0.070 |
Why?
|
| CD56 Antigen | 1 | 2008 | 26 | 0.070 |
Why?
|
| HLA-DR Antigens | 1 | 2008 | 66 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2008 | 40 | 0.070 |
Why?
|
| Cross-Priming | 1 | 2008 | 5 | 0.070 |
Why?
|
| Autoimmunity | 1 | 2009 | 175 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 2009 | 151 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2008 | 75 | 0.070 |
Why?
|
| Adenoviridae Infections | 1 | 2008 | 75 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2008 | 125 | 0.070 |
Why?
|
| Cell Separation | 1 | 2008 | 218 | 0.070 |
Why?
|
| Stomach Neoplasms | 2 | 2004 | 572 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1591 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2008 | 544 | 0.060 |
Why?
|
| Laparotomy | 1 | 2006 | 138 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2005 | 130 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2008 | 327 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4697 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2021 | 237 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2026 | 283 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1882 | 0.050 |
Why?
|
| Mitomycin | 1 | 2004 | 36 | 0.050 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 30 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 195 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 713 | 0.050 |
Why?
|
| Sepsis | 1 | 2008 | 493 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 1373 | 0.050 |
Why?
|
| Child | 3 | 2017 | 26341 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2002 | 100 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2003 | 152 | 0.050 |
Why?
|
| Gadolinium | 1 | 2003 | 110 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 101 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2022 | 236 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2022 | 93 | 0.040 |
Why?
|
| Leadership | 1 | 2024 | 255 | 0.040 |
Why?
|
| Floxuridine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Ribonucleotide Reductases | 1 | 2001 | 10 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2004 | 825 | 0.040 |
Why?
|
| Rats, Nude | 1 | 2001 | 10 | 0.040 |
Why?
|
| Proteins | 2 | 2004 | 1006 | 0.040 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 22 | 0.040 |
Why?
|
| Spectrophotometry | 1 | 2001 | 42 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 64 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 66 | 0.040 |
Why?
|
| Accreditation | 1 | 2021 | 89 | 0.040 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2001 | 43 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2001 | 136 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 116 | 0.040 |
Why?
|
| Mortality | 1 | 2002 | 264 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 311 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 165 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2000 | 59 | 0.040 |
Why?
|
| Cell Cycle Proteins | 3 | 2016 | 710 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2550 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 502 | 0.040 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 201 | 0.040 |
Why?
|
| Immunity | 1 | 2000 | 178 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 718 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2020 | 78 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2001 | 337 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2018 | 594 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 129 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 393 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 162 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2020 | 155 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 30 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 191 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 158 | 0.040 |
Why?
|
| Virus Replication | 1 | 2001 | 608 | 0.030 |
Why?
|
| Intention | 1 | 2019 | 105 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 209 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 1011 | 0.030 |
Why?
|
| Thymus Gland | 1 | 2018 | 104 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2018 | 59 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 1267 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 332 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2018 | 101 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 242 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 96 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 252 | 0.030 |
Why?
|
| Systems Biology | 1 | 2016 | 60 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 114 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 77 | 0.030 |
Why?
|
| Tissue Adhesions | 1 | 2015 | 26 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 89 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2001 | 807 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2016 | 122 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2015 | 30 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2015 | 26 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2016 | 1928 | 0.030 |
Why?
|
| Rats | 1 | 2001 | 3370 | 0.030 |
Why?
|
| Isoantibodies | 1 | 2015 | 59 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 335 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 335 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 256 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 82 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 429 | 0.030 |
Why?
|
| Hypotension | 1 | 2016 | 187 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 386 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 484 | 0.020 |
Why?
|
| Antigens, Differentiation | 2 | 2004 | 63 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 33 | 0.020 |
Why?
|
| Protein Phosphatase 1 | 2 | 2004 | 53 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 639 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2012 | 50 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1680 | 0.020 |
Why?
|
| Pregnancy | 2 | 2016 | 7512 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3763 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 63 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2009 | 112 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2009 | 22 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2008 | 114 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 69 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2008 | 246 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 124 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2008 | 235 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 2406 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2008 | 344 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 765 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 824 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 344 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 4686 | 0.010 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 84 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 761 | 0.010 |
Why?
|
| Virulence | 1 | 2004 | 268 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 224 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2004 | 148 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2121 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2885 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 664 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 15110 | 0.010 |
Why?
|
| Vero Cells | 1 | 2001 | 115 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 135 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2002 | 700 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 767 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 587 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2085 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 150 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 341 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 826 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2904 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 978 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 4497 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1618 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1481 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 991 | 0.010 |
Why?
|